Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.52 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.52 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.52 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896841 | 0.88 | FAAH (0.77) | FAAH | |
| SCHEMBL896789 | 0.88 | FAAH (0.70) | FAAH | |
| SCHEMBL897048 | 0.88 | FAAH (0.66) | FAAH | |
| SCHEMBL896917 | 0.87 | FAAH (0.64) | FAAHCYP2D6 | |
| SCHEMBL896733 | 0.87 | FAAH (0.83) | FAAH | |
| SCHEMBL896360 | 0.84 | FAAH (0.69) | FAAHCYP2D6 | |
| SCHEMBL896343 | 0.84 | FAAH (0.77) | FAAH | |
| SCHEMBL897046 | 0.83 | FAAH (0.61) | FAAHCYP2D6 | |
| SCHEMBL12991385 | 0.83 | FAAH (0.68) | FAAHCYP2D6 | |
| SCHEMBL896983 | 0.83 | FAAH (0.63) | FAAHCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | claimed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141817-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, DBH | FAAH 1/4885HIF1A 563/4885EPAS1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.